Keywords

2017, atopic dermatitis, eczema, FDA, FDA approved, new drugs, Parkinson disease, plaque psoriasis, rheumatoid arthritis, rosacea, type 2 diabetes mellitus, T2DM

Authors

1. Mospan, Geoffrey PharmD, BCPS
2. Mospan, Cortney PharmD, BCACP, BCGP
3. Vance, Shayna
4. Bradshaw, Alyssa
5. Meosky, Kalyn
6. Bowles, Kirklin

Abstract

Abstract: In 2017, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: brodalumab (Siliq), dapagliflozin and saxagliptin (Qtern), dupilumab (Dupixent), oxymetazoline (Rhofade), safinamide (Xadago), and sarilumab (Kevzara).